Known targets — ChEMBL curated mechanism
ACHEBDKRB2CHRM1CHRM2CHRM3CHRNA1CHRNB1CHRNDCHRNECHRNGGUCY1A1GUCY1A2GUCY1B1GUCY1B2NAMPTPTAFRSLC10A2SLC6A2SLC6A3TACR1dacAdacBdacCftsImrcAmrcBmrdA
The experimentally established mechanism targets of Ym-90K. The predicted profile below is derived independently by chemical similarity — agreement is a validation signal, a miss is honest.
Predicted protein targets (top 11)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | GRIA1 | P42261 | 3/20 | 0.97 |
| ▸ | GRIA2 | P42262 | 3/20 | 0.97 |
| ▸ | GRIA3 | P42263 | 3/20 | 0.97 |
| ▸ | GRIA4 | P48058 | 3/20 | 0.97 |
| ▸ | GRIK1 | P39086 | 2/20 | 0.97 |
| ▸ | GRIK2 | Q13002 | 2/20 | 0.97 |
| ▸ | GRIK3 | Q13003 | 2/20 | 0.97 |
| ▸ | GRIK4 | Q16099 | 2/20 | 0.97 |
| ▸ | GRIK5 | Q16478 | 2/20 | 0.97 |
| ▸ | SLC22A6 | Q4U2R8 | 1/20 | 0.61 |
| ▸ | SLC22A8 | Q8TCC7 | 1/20 | 0.61 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| Ym-90K SCHEMBL29798088 | 0.99 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL2049549 | 0.99 | GRIA1 (1.00) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL29384442 | 0.97 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Ym-90K SCHEMBL1055529 | 0.97 | GRIA1 (0.97) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL5723327 | 0.84 | GRIA1 (0.73) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL5723322 | 0.84 | GRIA1 (0.73) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL14142767 | 0.82 | GRIK1 (0.70) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL13227266 | 0.82 | SLC22A6 (0.71) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| SCHEMBL8682439 | 0.80 | GRIA1 (0.67) | GRIA1GRIA2GRIA3GRIA4GRIK1 | |
| Water SCHEMBL8145177 | 0.80 | GRIK1 (0.67) | GRIA1GRIA2GRIA3GRIA4GRIK1 |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 74 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA | 2020-01-30 | — | — | US | disclosed |
| WO-2018169798-A9 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-10-18 | — | — | WO | disclosed |
| WO-2018169798-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | THE REGENTS OF THE UNIVERSITY OF CALIFORNIA (US) | 2018-09-20 | — | — | WO | disclosed |
| WO-2012170599-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2012-12-13 | — | — | WO | disclosed |
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS INC. (US) | 2011-12-29 | — | — | US | disclosed |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | BRAINCELLS INC. (US) | 2011-11-03 | — | — | US | disclosed |
| EP-2382975-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-11-02 | — | — | EP | disclosed |
| EP-2377530-A2 | Modulation of neurogenesis by PDE inhibition | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| EP-2377531-A2 | Neurogenesis by modulating angiotensin | Braincells, Inc. (US) | 2011-10-19 | — | — | EP | disclosed |
| US-7998971-B2 | 2-(2-oxopyrrolidin- 1 -yl)-N-(2,3 -dimethyl-5,6,7,8-tetrahydrofuro[2,3-b]quinolin-4-yl)acetoamide (MKC-231) and a second active ingredient for treating central or peripheral nervous system disorders increase neurogenesis; synergistic; drug addiction, psychological disorders, transplant rejection | BRAINCELLS INC. (US) | 2011-08-16 | — | — | US | disclosed |
| WO-2007053596-A1 | GABA RECEPTOR MEDIATED MODULATION OF NEUROGENESIS | BRAINCELLS, INC. (US) | 2007-05-10 | — | — | WO | disclosed |
| WO-2007047978-A2 | MODULATION OF NEUROGENESIS BY PDE INHIBITION | BRAINCELLS, INC. (US) | 2007-04-26 | — | — | WO | disclosed |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | BRAINCELLS, INC. (US) | 2007-04-05 | — | — | US | disclosed |
| WO-2007030697-A2 | MODULATION OF NEUROGENESIS BY HDAC INHIBITION | BRAINCELLS, INC. (US) | 2007-03-15 | — | — | WO | disclosed |
| WO-2007025177-A2 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | WO | disclosed |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | BRAINCELLS, INC. (US) | 2007-03-01 | — | — | US | disclosed |
| US-20030073683-A1 | Administration of noncompetitive AMPA receptor antagonist for neuroprotection after traumatic brain injury | BELAYEV LUDMILA (US) | 2003-04-17 | — | — | US | disclosed |
| WO-2003024458-A1 | NEUROPROTECTION AFTER TRAUMATIC BRAIN INJURY | IVAX INSTITUTE FOR DRUG RESEARCH, INC. (US) | 2003-03-27 | — | — | WO | disclosed |
| US-6136812-A | Methods of administering AMPA receptor antagonists to treat dyskinesias associated with dopamine agonist therapy | PFIZER INC (US) | 2000-10-24 | — | — | US | disclosed |
| EP-0900568-A2 | AMPA antagonists for the treatment of dyskinesias associated with dopamine agonist therapy | Pfizer Products Inc. (US) | 1999-03-10 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (5 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20110319386-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | GRIA1 159/4885GRIA2 162/4885GRIA3 84/4885 |
| US-20200030304-A1 | MITIGATION OF CNS DISORDERS BY COMBINATION THERAPY USING NEUROSTEROIDS, AND AMPA BLOCKERS | GABRA4, GABRG1, GABRB2 | GRIA1 68/4885GRIA2 58/4885GRIA3 44/4885 |
| US-20070078083-A1 | MODULATION OF NEUORGENESIS BY HDac INHIBITION | DCX, BDNF, NTRK2 | GRIA1 288/4885GRIA2 210/4885GRIA3 128/4885 |
| US-20110269717-A1 | NEUROGENESIS BY MODULATING ANGIOTENSIN | NGF, DCX, BDNF | GRIA1 492/4885GRIA2 482/4885GRIA3 185/4885 |
| US-20070049576-A1 | NEUROGENESIS BY MUSCARINIC RECEPTOR MODULATION | CHRNB2, CHAT, CHRNB4 | GRIA1 159/4885GRIA2 162/4885GRIA3 84/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.